Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 392.96% from the stock’s previous close.

PYXS has been the subject of several other reports. Stephens increased their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Royal Bank Of Canada lowered their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Price Performance

NASDAQ:PYXS opened at $1.42 on Tuesday. The firm has a 50-day moving average of $1.53 and a 200-day moving average of $2.52. The company has a market cap of $88.41 million, a PE ratio of -0.89 and a beta of 1.45. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter. On average, equities research analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Maia Wealth LLC bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $25,000. Engineers Gate Manager LP purchased a new stake in shares of Pyxis Oncology during the fourth quarter valued at approximately $26,000. Fox Run Management L.L.C. bought a new stake in Pyxis Oncology during the fourth quarter worth $26,000. Avanza Fonder AB bought a new stake in Pyxis Oncology during the fourth quarter worth $31,000. Finally, XTX Topco Ltd purchased a new position in Pyxis Oncology in the second quarter worth $40,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.